OCX logo

OncoCyte (OCX) Cash From Operations

Annual CFO

-$23.32 M
+$22.24 M+48.81%

December 31, 2023


Summary


Performance

OCX Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherOCXcash flowmetrics:

Quarterly CFO

-$5.55 M
+$427.00 K+7.14%

September 30, 2024


Summary


Performance

OCX Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherOCXcash flowmetrics:

TTM CFO

-$19.78 M
-$1.78 M-9.90%

September 30, 2024


Summary


Performance

OCX TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherOCXcash flowmetrics:

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

OCX Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+48.8%-47.3%+30.7%
3 y3 years+10.2%+50.6%+53.5%
5 y5 years-100.2%+50.6%+53.5%

OCX Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+48.8%-47.3%+58.2%-9.9%+56.6%
5 y5-year-18.3%+48.8%-47.3%+58.2%-9.9%+56.6%
alltimeall time-3185.2%+48.8%-3284.8%+58.2%<-9999.0%+56.6%

OncoCyte Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2024
-
-$5.55 M(-7.1%)
-$19.78 M(+9.9%)
Jun 2024
-
-$5.98 M(+56.1%)
-$18.00 M(-4.5%)
Mar 2024
-
-$3.83 M(-13.4%)
-$18.86 M(-19.2%)
Dec 2023
-$23.32 M(-48.8%)
-$4.42 M(+17.4%)
-$23.32 M(-18.3%)
Sep 2023
-
-$3.77 M(-44.8%)
-$28.55 M(-21.1%)
Jun 2023
-
-$6.83 M(-17.7%)
-$36.18 M(-10.9%)
Mar 2023
-
-$8.30 M(-14.0%)
-$40.59 M(-10.9%)
Dec 2022
-$45.57 M(+26.8%)
-$9.65 M(-15.3%)
-$45.57 M(+6.0%)
Sep 2022
-
-$11.40 M(+1.3%)
-$42.98 M(+1.0%)
Jun 2022
-
-$11.25 M(-15.3%)
-$42.57 M(+8.1%)
Mar 2022
-
-$13.28 M(+87.9%)
-$39.38 M(+9.6%)
Dec 2021
-$35.94 M(+38.3%)
-$7.07 M(-35.7%)
-$35.94 M(+2.6%)
Sep 2021
-
-$10.98 M(+36.3%)
-$35.02 M(+16.6%)
Jun 2021
-
-$8.06 M(-18.1%)
-$30.04 M(+3.8%)
Mar 2021
-
-$9.84 M(+60.1%)
-$28.95 M(+11.4%)
Dec 2020
-$25.98 M(+31.8%)
-$6.14 M(+2.3%)
-$25.98 M(+3.3%)
Sep 2020
-
-$6.00 M(-13.7%)
-$25.14 M(+4.8%)
Jun 2020
-
-$6.96 M(+1.3%)
-$23.99 M(+20.7%)
Mar 2020
-
-$6.87 M(+29.5%)
-$19.87 M(+0.8%)
Dec 2019
-$19.71 M
-$5.31 M(+9.4%)
-$19.71 M(+16.9%)
DateAnnualQuarterlyTTM
Sep 2019
-
-$4.85 M(+70.8%)
-$16.86 M(+16.3%)
Jun 2019
-
-$2.84 M(-57.7%)
-$14.50 M(-7.2%)
Mar 2019
-
-$6.72 M(+173.5%)
-$15.61 M(+34.0%)
Dec 2018
-$11.65 M(-13.0%)
-$2.46 M(-1.1%)
-$11.65 M(-7.1%)
Sep 2018
-
-$2.48 M(-37.3%)
-$12.54 M(-7.3%)
Jun 2018
-
-$3.96 M(+43.7%)
-$13.52 M(+5.3%)
Mar 2018
-
-$2.75 M(-17.7%)
-$12.85 M(-4.0%)
Dec 2017
-$13.38 M(+77.9%)
-$3.34 M(-3.6%)
-$13.38 M(+6.6%)
Sep 2017
-
-$3.47 M(+5.8%)
-$12.55 M(+24.1%)
Jun 2017
-
-$3.28 M(-0.3%)
-$10.12 M(+17.1%)
Mar 2017
-
-$3.29 M(+30.9%)
-$8.64 M(+14.9%)
Dec 2016
-$7.52 M(+77.9%)
-$2.51 M(+143.1%)
-$7.52 M(+12.2%)
Sep 2016
-
-$1.03 M(-42.8%)
-$6.70 M(-5.0%)
Jun 2016
-
-$1.81 M(-16.6%)
-$7.05 M(+13.2%)
Mar 2016
-
-$2.17 M(+27.8%)
-$6.23 M(+47.4%)
Dec 2015
-$4.23 M(+263.3%)
-$1.70 M(+22.3%)
-$4.23 M(+66.9%)
Sep 2015
-
-$1.39 M(+40.9%)
-$2.53 M(+120.7%)
Jun 2015
-
-$984.00 K(+500.0%)
-$1.15 M(+600.0%)
Mar 2015
-
-$164.00 K
-$164.00 K
Dec 2014
-$1.16 M(+63.9%)
-
-
Dec 2013
-$710.00 K
-
-

FAQ

  • What is OncoCyte annual cash flow from operations?
  • What is the all time high annual CFO for OncoCyte?
  • What is OncoCyte annual CFO year-on-year change?
  • What is OncoCyte quarterly cash flow from operations?
  • What is the all time high quarterly CFO for OncoCyte?
  • What is OncoCyte quarterly CFO year-on-year change?
  • What is OncoCyte TTM cash flow from operations?
  • What is the all time high TTM CFO for OncoCyte?
  • What is OncoCyte TTM CFO year-on-year change?

What is OncoCyte annual cash flow from operations?

The current annual CFO of OCX is -$23.32 M

What is the all time high annual CFO for OncoCyte?

OncoCyte all-time high annual cash flow from operations is -$710.00 K

What is OncoCyte annual CFO year-on-year change?

Over the past year, OCX annual cash flow from operations has changed by +$22.24 M (+48.81%)

What is OncoCyte quarterly cash flow from operations?

The current quarterly CFO of OCX is -$5.55 M

What is the all time high quarterly CFO for OncoCyte?

OncoCyte all-time high quarterly cash flow from operations is -$164.00 K

What is OncoCyte quarterly CFO year-on-year change?

Over the past year, OCX quarterly cash flow from operations has changed by -$1.78 M (-47.28%)

What is OncoCyte TTM cash flow from operations?

The current TTM CFO of OCX is -$19.78 M

What is the all time high TTM CFO for OncoCyte?

OncoCyte all-time high TTM cash flow from operations is -$164.00 K

What is OncoCyte TTM CFO year-on-year change?

Over the past year, OCX TTM cash flow from operations has changed by +$8.77 M (+30.71%)